Spero Therapeutics, Inc. (SPRO) announced on Wednesday that the FDA cleared its investigational new drug or IND application to evaluate SPR206 in a Phase 2 clinical trial.
SPR206 is a new intravenous polymyxin antibiotic intended to address hospital-acquired and ventilator-associated bacterial pneumonia-like HABP/VABP due to multidrug-resistant Gram-negative bacterial infections.
The Phase 2 trial will assess the safety, effectiveness, and pharmacokinetics of SPR206 combined with specific antibiotics to treat HABP or VABP caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex or carbapenem-resistant Pseudomonas aeruginosa.
Around 60 hospitalized adults will be enrolled and treated for 7-14 days, with their progress evaluated based on post-baseline clinical outcomes.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.